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Abstract
Background: Several theories have been proposed to conceptualize the pathological processes inherent to
schizophrenia. The ‘prostaglandin deficiency’ hypothesis postulates that defective enzyme systems converting
essential fatty acids to prostaglandins lead to diminished levels of prostaglandins, which in turn affect synaptic
transmission.
Methods: Here we sought to determine the lipidomic profiles associated with schizophrenia in twin pairs
discordant for schizophrenia as well as unaffected twin pairs. The study included serum samples from 19 twin pairs
discordant for schizophrenia (mean age 51 ± 10 years; 7 monozygotic pairs; 13 female pairs) and 34 age and
gender matched healthy twins as controls. Neurocognitive assessment data and gray matter density measurements
taken from high-resolution magnetic resonance images were also obtained. A lipidomics platform using ultra
performance liquid chromatography coupled to time-of-flight mass spectrometry was applied for the analysis of
serum samples.
Results: In comparison to their healthy co-twins, the patients had elevated triglycerides and were more insulin
resistant. They had diminished lysophosphatidylcholine levels, which associated with decreased cognitive speed.
Conclusions: Our findings may be of pathophysiological relevance since lysophosphatidylcholines, byproducts of
phospholipase A2-catalyzed phospholipid hydrolysis, are preferred carriers of polyunsaturated fatty acids across the
blood-brain barrier. Furthermore, diminishment of lysophosphatidylcholines suggests that subjects at risk of
schizophrenia may be more susceptible to infections. Their association with cognitive speed supports the view that
altered neurotransmission in schizophrenia may be in part mediated by reactive lipids such as prostaglandins.
Background
Several theories have been proposed to conceptualize the
pathological processes inherent to schizophrenia, among
others altered neurotransmission, autoimmune dysfunc-
tion and dysregulation of inflammation [1,2]. The phos-
pholipid hypothesis suggests that deficient uptake or
excessive breakdown of membrane phospholipids or
changes in membrane phospholipid composition may be
associated with schizophrenia [3]. The hypothesis is
supported by studies finding lipid abnormalities both in
postmortem gray and white matter samples and from per-
ipheral red blood cells of patients with schizophrenia [4].
Moreover, phospholipase A2 activity is increased particu-
larly in the first-onset patients with schizophrenia and
associates with structural brain changes, particularly in the
prefrontal cortex and thalamus [5]. Nevertheless, the evi-
dence for the phospholipid hypothesis is not conclusive
[6]. Prior to the phospholipid hypothesis, a prostaglandin
deficiency hypothesis was proposed [7]. Phospholipid
abnormalities and prostaglandin deficiency may be related
since prostaglandins are synthesized via hydrolysis of
phosphatidylcholine (PC) by action of phospholipase A2,
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tidylcholines (lysoPCs).
Directly addressing the phospholipid and prostaglandin
hypotheses by measuring the relevant phospholipids and
prostaglandins has been difficult until recently. Even
today, reliable measurements of prostaglandins from clini-
cal samples are-despite the availability of sensitive instru-
ments and analytical techniques-very challenging to make
due to sensitivity of prostaglandins to sample collection
and pre-treatment. However, the emergence of metabolo-
mics, and with it also lipidomics [8], a global study of
lipids, has enabled comprehensive and sensitive measure-
ment of molecular lipids, including phospholipids in bio-
fluids and tissues. Here we sought to determine the
lipidomic profiles associated with schizophrenia in twin
pairs discordant for schizophrenia as well as unaffected
twin pairs. The use of twin pairs discordant for the disor-
der enables separation of lipidomic profiles associated
with genetic liability to disorder from those associated
with illness expression or treatment.
Materials and methods
Participants and clinical evaluation
Same-sex twin pairs discordant for schizophrenia were
identified from Finnish national registers, as described in
detail in Cannon et al.[ 9 ] ,a n di n t e r v i e w e dw i t ht h e
Structured Clinical Interview for the Diagnostic and Sta-
tistical Manual of Mental Disorders (DSM)-III-R [10];
diagnoses were assigned according to the DSM-IV [11].
The procedures for determining diagnoses and zygosity
have been presented in detail by Cannon et al. [12]. Only
patients with a confirmed diagnosis of schizophrenia who
were not inpatients at the time were asked to participate
in the blood sampling. Healthy control twin pairs
selected from the Finnish Twin Cohort were matched by
age and gender. Demographic information is presented
in Table 1.
Symptom severity was quantified on the Scale for the
Assessment of Negative Symptoms (SANS) and the
Scale for the Assessment of Positive Symptoms (SAPS)
[13,14]. Patients had, on average, mild to moderate
negative symptoms (SANS mean ± standard deviation
1.3 ± 0.9, with personal maximums of 2.5 ± 1.0) and
moderate positive symptoms (SAPS mean ± standard
deviation 2.0 ± 0.8, with personal maximums of 3.5 ±
0.9). Two patients met criteria for remission [15].
All participants took part in an extensive neurocogni-
tive assessment with established tasks known to be sen-
sitive to cognitive deficits in schizophrenia. The
cognitive tasks used and the rationale for their inclusion
have been presented before in detail [16]. Cognitive
results are presented in Additional file 1.
The study protocol was reviewed and approved by the
institutional review boards of the National Public Health
Institute, Helsinki, Finland, and the University of Cali-
fornia-Los Angeles, and all participants signed institu-
tional review board-approved informed consent forms.
Image acquisition and analysis
T1-weighted MPRAGE MRI volumes were acquired on a
1.5-Tesla scanner (Siemens, Iselin, NJ, USA) in the
Department of Radiology at Helsinki University Central
Hospital (128 contiguous 1.2-mm slices in the sagittal
plane, repetition time 11.4, echo time 4.4, 256 × 256
matrix). A radio-frequency bias field-correction algorithm
eliminated intensity drifts caused by scanner field inhomo-
geneity. Cerebral images were automatically extracted
from the scans, manually edited, and classified into gray
matter, white matter, and cerebrospinal fluid components.
High-resolution surface models of cerebral hemi-
spheres were generated automatically for each partici-
pant. Raters blind to diagnostic and demographic
information drew 36 gyral and sulcal landmarks, repre-
senting the primary gyral pattern, as three-dimensional
curves on each of the surface models by using a detailed
anatomical protocol [17,18]. Raters were trained on a set
of six brains until they were able to trace landmarks with
three-dimensional deviations no greater than 4 mm
everywhere and 2 mm on average when compared with
‘gold standard’ tracing.
The hemispheric surfaces were elastically warped to
each other based on matching individual curves to their
corresponding average curves, and three-dimensional
deformation fields were obtained. A local measurement
termed gray-matter density (GMD) was calculated for
each individual, whereby the proportion of gray matter is
measured in a sphere of fixed radius (15 mm) around each
cortical point. This proportion thus reflects the amount of
local gray matter in the sphere. Maps representing the
variability in GMD across cortex were then generated for
all individuals and were used in further analysis.
The GMD data were available from 34 participants (9
patients, 9 co-twins, and 16 controls). The imaging and
neurocognitive data were collected on average 5 years
prior to blood sampling for this specific study.
Insulin and glucose assays
Serum concentrations of insulin and glucose were ana-
lyzed at the Finnish National Institute for Health and
Welfare using Architect ci8200 analyzer (Abbott Labora-
tories, Abbott Park, IL, USA). The inter-assay coefficient
of variation of insulin varied from 1.5% (low level control,
26 mU/L) to 2.7% (high level control, 166 mU/L). The
inter-assay coefficient of variation of glucose was 2.0%.
Lipidomic analysis
EDTA-blood samples (10 ml) were centrifuged at 3,200
rpm (1,600G) for 15 minutes at room temperature
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a n ds t o r e da t- 8 0 ° C .F o rl i p i d o m i c sp r o f i l i n g ,1 0μla l i -
quots of serum were used. The samples were mixed
with 10 μl of 0.9% sodium chloride in Eppendorf tubes,
spiked with a standard mixture consisting of 10 lipids
(0.2 μg/sample; lysophosphatidylcholine LPC(17:0/0:0),
phosphatidylcholine PC(17:0/17:0), phosphatidylethano-
lamine PE(17:0/17:0), phosphatidylglycerol PG(17:0/
17:0), ceramide Cer(d18:1/17:0), phosphatidylserine PS
(17:0/17:0), phosphatidic acid PA(17:0/17:0), monogly-
ceride MG(17:0/0:0/0:0), diglyceride DG(17:0/17:0/0:0),
triglyceride TG(17:0/17:0/17:0)) and extracted with
100 μl of chloroform/methanol (2:1). After vortexing (2
minutes) and standing (1 hour) the tubes were centri-
fuged at 10,000 rpm for 3 minutes and 60 μlo ft h e
lower organic phase was separated and spiked with a
standard mixture containing three labeled lipids (0.1 μg/
sample; LPC(16:1/0:0-D3), PC(16:1/16:1-D6), TG(16:0/
16:0/16:0-
13C3)).
Lipid extracts were analyzed in a randomized order on
a Waters Q-Tof Premier mass spectrometer combined
with an Acquity Ultra Performance LC™ (UPLC). The
column (at 50°C) was an Acquity UPLC™B E HC 1 81×
50 mm with 1.7 μm particles. The solvent system
included 1) ultrapure water (1% 1 M NH4Ac, 0.1%
HCOOH) and 2) liquid chromatography/mass spectro-
metry grade acetonitrile/isopropanol (5:2, 1% 1 M
NH4Ac, 0.1% HCOOH). The gradient started from 65%
A/35% B, reached 100% B in 6 minutes and remained
there for the next 7 minutes. There was a 5-minute re-
equilibration step before the next run. The flow rate was
0.200 ml/minute and the injected amount was 1.0 μl
(Acquity Sample Organizer). Reserpine was used as the
lock spray reference compound. The lipid profiling was
carried out using ESI+ mode and the data were collected
at mass range of m/z 300 to 1,200 with a scan duration
of 0.2 s. The data were processed by using MZmine 2
software [19] and the lipid identification was based on an
internal spectral library.
T h ed a t aw e r en o r m a l i z e du s i n go n eo rm o r ei n t e r n a l
standard representatives of each class of lipid present in the
samples [20]: the intensity of each identified lipid is normal-
ized by dividing it with the intensity of its corresponding
standard and multiplying it by the concentration of the
standard. All monoacyl lipids except cholesterol esters,
such as monoacylglycerols and monoacylglycerophospholi-
pids, were normalized with PC(17:0/0:0), all diacyl lipids
except ethanolamine phospholipids were normalized with
PC(17:0/17:0), all ceramides with Cer(d18:1/17:0), all diacyl
ethanolamine phospholipids with PE(17:0/17:0), and TG
and cholesterol esters with TG(17:0/17:0/17:0). Other (uni-
dentified) molecular species were calibrated with PC(17:0/
0:0) for retention time < 300 s, PC(17:0/17:0) for retention
time between 300 s and 410 s, and TG(17:0/17:0/17:0) for
higher retention times.
Statistical analysis of lipidomics data
Linear mixed models were applied to the twin-pair data
using the R statistical language v2.13 [21], implemented
in R package nlme. Intra-pair correlations were treated as
random effects in the model. The overall group differ-
ence was tested using F-statistic and the post-hoc ana-
lyses were done using Tukey’s all-pair comparisons. The
adjusted P-value for each comparison was computed
using multiple testing procedures under free combina-
tions (R package multcomp, option ‘free’ in the summary
function).
Individual metabolite levels were visualized using the
beanplot [22] algorithm implemented in R. A beanplot
provides information on the mean metabolite level
within each group and the density of the data-point dis-
tribution and also shows individual data points.
Table 1 Demographic and metabolic characteristics of the study population, shown for patients, their unaffected co-
twins, patients and their co-twins combined (discordant twin pairs), and the controls
Characteristic Controls Unaffected co-twins Patients P (F-test)
N 34 19 19
Monozygotic 20 (10 pairs) 7 7
Female 24 13 13
Age (years)
a 53.4 (50.2, 56.6) 51.0 (46.4, 55.6) 51.0 (46.4, 55.6)
Diabetes 0 1 7
Antipsychotic medication (atypical antipsychotics)
b 0 0 15 (14)
Cholesterol medication 2 0 6
BMI 25.4 (23.8, 27.0)** 25.7 (24.0, 27.5)** 29.2 (26.5, 31.9) 0.020
Insulin
c 7.7 (5.9, 9.9) 8.9 (6.9, 11.6)* 14.1 (9.1, 21.7) 0.085
Glucose
c 5.07 (4.78, 5.38) 5.30 (4.54, 6.19) 5.76 (4.87, 6.80) 0.40
HOMA-IR
c 1.72 (1.30, 2.29) 2.11 (1.52, 2.93)** 3.61 (2.22, 5.86) 0.062
aData for this and other variables are shown as mean (95% confidence interval).
bAccording to self-report.
cGeometric means and confidence intervals; statistics
estimated from log10-transformed data. *P < 0.1, **P < 0.05 (post-hoc analysis using Tukey all-pair comparisons versus the patient group; no comparisons were
significant between the controls and unaffected co-twins). BMI, body mass index; HOMA-IR, Homeostasis Model Assessment index.
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iance to obtain metabolite profiles comparable to each
other for clustering. Bayesian model-based clustering
was applied on the scaled data to group lipids into clus-
ters. The analyses were performed using the MCLUST
[23] method, implemented in R [21].
Statistical analysis of image data
To reduce GMD data and facilitate network analysis, inde-
pendent component analysis was applied to GMD maps
from all individuals, using the FastICA algorithm in the
Modular toolkit for Data Processing [24]. Each indepen-
dent component was examined on three-dimensional cor-
tical surface maps and the weights for all individuals in the
mixing matrix were used in the network analysis.
Partial correlation network analysis
Construction of the dependency network for selected vari-
ables was performed using undirected Gaussian graphical
Markov networks that represent q-order partial correla-
tions between variables (the so called QPGRAPH method),
implemented in an R package ‘qpgraph’ from the Biocon-
ductor project [25]. In these networks non-missing edges
denote non-zero partial correlations between pairs of vari-
ables and thus imply direct interactions. The network was
visualized using yED graphical editor [26].
Results
Associations of the global lipidome with schizophrenia
Using the lipidomics platform, a total of 530 molecular
lipids were detected, of which 250 were identified (the full
dataset is provided in Additional file 2). Due to a high
degree of co-regulation among the lipids, one cannot
assume that all the 530 measured lipids are independent.
The global lipidome was therefore first surveyed by clus-
tering the data into a subset of clusters using Bayesian
model-based clustering. Lipidomic platform data were
decomposed into seven clusters. Descriptions of each clus-
ter and representative lipids are given in Table 2. As
expected, the division of clusters to a large extent follows
different lipid functional or structural groups.
As shown in Figure 1a, the major differences observed
were in clusters LC4 and LC5, corresponding to lysoPCs
and abundant TGs, respectively. LysoPCs were dimin-
ished in schizophrenia patients compared to their co-
t w i n sa sw e l la sh e a l t h yc o n t r o l s( F i g u r e1 b ) .T G sf r o m
LC5 were elevated in patients compared to their co-twins
(Figure 1b), but there were no differences between the
healthy twins from schizophrenia-discordant pairs and
controls. In the large phospholipid cluster LC2, while no
changes were observed for the cluster overall, the major
lipid-class-specific changes were observed for sphingo-
myelins, which were elevated in patients compared to
their healthy co-twins (Figure 1b shows one representa-
tive abundant sphingomyelin).
The observed differences in lipidomes were accompa-
nied by differences in metabolic and body composition
characteristics (Table 1). Patients had higher body mass
index (BMI), insulin (at marginal significance level) and
Homeostasis Model Assessment index (HOMA-IR) than
their unaffected co-twins. No differences in glucose
levels were observed.
Dependency analysis
Next, we investigated the associations between the
observed metabolic and body compositional changes and
the earlier acquired neurocognitive and image data. The
included 21 neurocognitive variables are listed in Addi-
tional file 1. MRI data were first decomposed by indepen-
dent component analysis into 34 independent components
(ICs), of which 14 were included in the dependency net-
work analysis. The selection criteria were (1) known rele-
vance of the represented region to schizophrenia or (2)
differences between the groups were at the P < 0.15 level.
The selected ICs are described in Additional file 3. In
addition to the seven lipid clusters (LCs; Figure 1), other
variables included in the analysis were age, BMI, fasting
plasma glucose and insulin as well as HOMA-IR.
Table 2 Description of lipid clusters obtained from lipidomics platform
Cluster name Cluster size Description Representative abundant lipids P (F-test)
LC1 68 Mainly ether lipids PE(36:6e), PC(34:4e) 0.39
LC2 211 Sphingomyelins, major phospholipids SM(d18:1/18:0), SM(d18:1/24:1), PC(34:2) 0.69
LC3 49 PUFA-containing PCs and PEs PC(38:6), PE(38:5) 0.91
LC4 25 LysoPCs lysoPC(18:0), lysoPC(20:3) 0.096
a
LC5 76 Abundant TGs TG(16:0/18:1/18:1), TG(18:1/18:2/18:1) 0.061
b
LC6 35 Long-chain TGs; PUFA-containing TGs TG(56:6), TG(58:8), TG(58:9) 0.25
LC7 66 Mainly shorter-chain SFAs and MUFA-containing TGs TG(14:0/16:0/18:1), TG(14:0/16:0/18:0) 0.65
aTukey’s all-pair comparison: P = 0.12 (patients versus co-twins), P = 0.078 (co-twins versus controls), P = 0.56 (patients versus controls).
bTukey’s all-pair
comparison: P = 0.039 (patients versus co-twins), P = 0.44 (co-twins versus controls), P = 0.24 (patients versus controls). LC, LC, lipid cluster; lysoPC,
lysophosphatidylcholine; MUFA, monounsaturated fatty acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PUFA, polyunsaturated fatty acid; SFA,
saturated fatty acid; SM, sphingomyelin; TG, triglyceride.
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Figure 1 Lipid levels across the three study groups, as obtained from the lipidomics platform. (a) Mean lipid levels within each cluster.
Error marks show standard error of the mean. The F-test (across the three groups) P-values are shown. (b) Profiles of selected representative
abundant lipids from three clusters. lysoPC(16:0) and lysoPC(18:0) are the two most abundant lysophosphatidylcholines measured in plasma. The
lipid levels are shown as beanplots [22], which provide information on the mean level (solid line), individual data points (short lines), and the
density of the distribution. Note that the concentration scale in beanplots is logarithmic. Tukey all-pair comparison post-hoc test: patients versus
co-twins (*P < 0.1, **P < 0.05, ***P < 0.001), patients versus controls (
†P < 0.1,
††P < 0.05,
†††P < 0.01). No significant differences were found
when comparing co-twins and controls. CoTw, unaffected co-twins; Ctr, controls; Sch, patients.
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49 variables, we utilized the QPGRAPH method, which
has been previously applied to study gene regulatory net-
works based on microarray data [25] as well as in our
earlier population-based metabolomics study of psy-
choses [27]. QPGRAPH uses partial correlations as a
measure of dependency and builds an undirected Gaus-
sian graphical model where the variables are connected if
and only if their partial correlation is significantly non-
zero. Unlike the commonly applied pairwise measure of
associations such as Pearson correlation coefficients, par-
tial correlation provides a stronger criterion for depen-
dency by adjusting for the confounding effects and thus
removes spurious associations to a large extent.
As expected, the TG clusters LC5 to LC7 were
strongly associated with the metabolic variables, includ-
ing BMI and HOMA-IR (Figure 2). Network analysis
did not reveal direct associations of TG clusters with
any of the MRI-derived independent components, but
the direct cortical mapping of the TG cluster LC5
revealed that this cluster is positively correlated with
gray matter density in lateral temporal surfaces on both
sides and medial occipital and parietal surfaces on the
right side (Figure 3).
The lysoPC cluster LC4 was associated with neurocog-
nitive variables related to cognitive speed, especially with
Trail Making Task A (TMT-A) response time, and was
also close to Trail Making Task B (TMT-B) response
time, WAIS-R Digit Symbol score, and Stroop Color
Word Response Time. TMT-A was associated with five
GMD independent components, among which IC2
(right precentral areas) was increased in twin pairs dis-
cordant for schizophrenia compared to controls, and
IC5 (superior temporal gyri) was decreased at a marginal
significance level (Figure 2). Direct cortical mapping of
abundant lysoPC(18:0) revealed positive correlation with
gray matter density mainly in right precentral gyrus,
anterior cingulate areas, and medial parietal and occipi-
tal surfaces (Figure 3).
Discussion
Our findings based on a well-phenotyped cohort of twin
pairs discordant for schizophrenia and healthy controls
independently associate specific lipid abnormalities with
schizophrenia and with genetic liability to schizophrenia
as well as with specific intermediate phenotypes obtained
from brain imaging and neurocognitive testing.
The observed elevation of triglycerides in schizophrenia
patients in comparison to their healthy co-twins is in
agreement with earlier findings that schizophrenia is
associated with elevated fasting total triglycerides and
insulin resistance [27,28]. This metabolic abnormality has
been usually attributed to antipsychotic drug-specific side
effects. However, there is growing evidence that elevated
circulating insulin and insulin-related peptides and
abnormal insulin response to glucose can be identified
already in drug-naïve first-episode patients [29-32], sug-
gesting that insulin signaling is impaired in schizophrenia
[30,31].
In a recent lipidomic study of different lipoprotein
fractions in people with varying degrees of insulin resis-
t a n c ew ef o u n dt h a tt h el i p i d so b s e r v e di nL C 5a r e
abundant in liver-produced very low density lipoprotein
particles and are associated with insulin resistance [33].
In agreement with this, schizophrenia patients in the
present study were insulin resistant. Additionally, the
twins from pairs discordant for schizophrenia had a
higher HOMA-IR index compared to healthy controls
(Table 1), implying that these differences may not be
due to antipsychotic medication use.
One should bear in mind that atypical antipsychotics
used by a majority of patients in our study (Table 1) are
known to have a strong effect on serum lipidomic pro-
files [34]. Consequently, with the data from the current
study alone we are not able to control for the effect of
antipsychotic medication used on lipidomic profiles, spe-
cifically on the elevated triglycerides in the patients.
However, we have already shown in our earlier study that
triglycerides are significantly elevated in schizophrenia
patients even after correcting for antipsychotic medica-
tion use and metabolic co-morbidity [27]. Furthermore,
previous studies finding elevated insulin and related pep-
tides have been done on antipsychotic-naïve first-episode
patients [29-31]. Together, our data indicate that schizo-
phrenia is characterized by insulin resistance and conse-
quently enhanced hepatic very low density lipoprotein
production [35] and elevated serum concentrations of
specific triglycerides.
LysoPCs were diminished in schizophrenia patients
compared to their co-twins and to healthy controls.
These changes were associated with decreased cognitive
speed. The observed changes are particularly remarkable
because elevated lysoPCs commonly positively associate
with obesity and insulin resistance, as we have shown in
a study of monozygous twins pairs discordant for weight
[36]. Despite having measured lysoPC from serum, its
observed variation may have direct implications for the
lipid metabolism in the brain since lysoPC is a preferred
carrier of polyunsaturated fatty acids across the blood-
brain barrier [37]. Polyunsaturated fatty acids are impor-
tant for the development of normal brain function [3]. In
individuals at ultra-high risk of a psychotic disorder, diet-
ary intake of long chain ω-3 fatty acids also reduces the
risk of progression to the disease [38].
One potential clue about the pathogenic relevance of
our findings comes from the negative association of
rheumatoid arthritis with schizophrenia. Oken and
Schulzer [39] performed a meta-analysis of 16 studies
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Page 7 of 10encompassing over 70,000 patients with schizophrenia
and over 350,000 patients with other major psychiatric
conditions and concluded that rheumatoid arthritis
‘occurs among schizophrenia patients at a rate of only
29 percent of the corresponding prevalence in other
psychiatric patients’ and is even lower than 29% when
compared to the general population. Such negative asso-
ciation with schizophrenia led to the ‘prostaglandin defi-
ciency’ hypothesis, which postulated that defective
enzyme systems converting essential fatty acids to pros-
taglandins lead to diminished levels of prostaglandins
[7], which as a consequence may lead to altered monoa-
minergic neurotransmission. Prostaglandins are-along
with lysoPCs-byproducts of PC hydrolysis by phospholi-
pase A2. In contrast to schizophrenia, lysoPC is
increased in rheumatoid arthritis [40], thus supporting
the view that prostaglandins and perhaps also lysoPC as
a byproduct may play a protective role in schizophrenia.
As an alternative hypothesis, based also on the evidence
that infections in early life may play a role in etiology of
schizophrenia [41], Torrey and Yolken [42] suggested
that rheumatoid arthritis and schizophrenia ‘share a
common infectious and/or immune etiology and that
once a person gets one of the diseases then they are
relatively immune to the other’. In fact, these two
hypotheses may be related. Prolonged low levels of
lysoPC in early life increases susceptibility to infection
[43]. Recent research in sepsis has also shown that
lysoPC inversely correlates with the severity of infection
[44] and that lysoPC administration to mouse models of
sepsis protects them against lethality [45].
LysoPC is a major component of oxidized low density
lipoprotein [46], but varying serum lysoPC concentra-
tions may also be due to changes in high density lipopro-
tein (HDL) metabolism. LysoPC is particularly abundant
in persons with high HDL cholesterol [47] and dimin-
ished levels of HDL cholesterol have been observed in
patients with schizophreniai nag e n e r a lp o p u l a t i o n
cohort [48]. Together, due to many sources influencing
lysoPC concentration in blood, which may depend on the
individual’s genotype and lifestyle, it may be challenging
to detect disease-specific changes of lysoPCs in the gen-
eral population, such as in our recent study in a general
population cohort [27]. The twin study design such as
ours is a more suitable setting where genetic and envir-
onmental factors are better separated, and specific factors
directly associated with the disease pathogenesis may be
more sensitively detected.
As a potential limitation of our study, the imaging and
neurocognitive data were collected on average 5 years
prior to blood sampling for this specific study. However,
there is recent evidence that correlation between age and
cortical thickness is similar in patients and controls [49].
In a two-year longitudinal study of first-episode psy-
choses, neurocognitive deficits were found in place by
onset of psychosis and remained stable over the course of
the study [50]. We therefore consider that brain structure
and cognitive performance would not change within this
span to a degree or in a direction that would affect the
conclusions being drawn from the data. However, the
fact that the imaging data were available for only 34 out
of 73 participants weakened the power of the association
lysoPC(18:0) (LC4)  TG cluster (LC5) 
Figure 3 Significant correlations between lipid levels and cortical gray matter density. LysoPC(18:0) level is positively correlated with gray
matter density mainly in right precentral gyrus, anterior cingulate areas, and medial parietal and occipital surfaces. The triglyceride cluster LC5i s
positively correlated with gray matter density in lateral temporal surfaces on both sides and medial occipital and parietal surfaces on the right
side. These results were confirmed using permutation tests.
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Page 8 of 10analysis of image data with other variables. Another
potential limitation is the cross-sectional design of our
study. Due to many sources affecting lysoPC concentra-
tion, longitudinal research in prodromal and early psy-
chosis is needed to further elucidate its role in psychotic
disorders. Finally, a more decisive separation of genetic
versus environmental effects would have come from
examining the monozygous twin pairs separately, but the
numbers are too small to permit this.
Conclusions
Our study suggests that insulin resistance and the related
elevation of specific triglycerides are inherent features of
schizophrenia. Furthermore, diminishment of lysoPCs
suggests that subjects at risk of schizophrenia may be
more susceptible to infections. Their association with
cognitive speed supports the view that altered neuro-
transmission in schizophrenia is in part mediated by
reactive lipids such as prostaglandins. Further studies are
needed to confirm these findings as well as to establish
the cause and mechanism of the altered lysoPC levels
and their relation to psychosis.
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